The sandhoff disease therapeutics market is projected to grow from USD 11.2 billion in 2025 to USD 20.1 billion by 2035, at a CAGR of 6.0%. Gene Therapy will dominate with a 57.3% market share, while acute infantile sandhoff disease will lead the type segment with a 48.6% share.